DK4274838T3 - Bicykliske peptidligander, der er specifikke for NK-celler - Google Patents
Bicykliske peptidligander, der er specifikke for NK-celler Download PDFInfo
- Publication number
- DK4274838T3 DK4274838T3 DK22700425.6T DK22700425T DK4274838T3 DK 4274838 T3 DK4274838 T3 DK 4274838T3 DK 22700425 T DK22700425 T DK 22700425T DK 4274838 T3 DK4274838 T3 DK 4274838T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- peptide ligands
- ligands specific
- bicyclic peptide
- bicyclic
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 210000000822 natural killer cell Anatomy 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135339P | 2021-01-08 | 2021-01-08 | |
| US202163262597P | 2021-10-15 | 2021-10-15 | |
| PCT/GB2022/050043 WO2022148974A2 (en) | 2021-01-08 | 2022-01-10 | Bicyclic peptide ligands specific for nk cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4274838T3 true DK4274838T3 (da) | 2024-10-21 |
Family
ID=79830970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22700425.6T DK4274838T3 (da) | 2021-01-08 | 2022-01-10 | Bicykliske peptidligander, der er specifikke for NK-celler |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240108738A1 (da) |
| EP (1) | EP4274838B1 (da) |
| JP (1) | JP2024502351A (da) |
| AU (1) | AU2022206394A1 (da) |
| CA (1) | CA3217018A1 (da) |
| DK (1) | DK4274838T3 (da) |
| ES (1) | ES2992468T3 (da) |
| IL (1) | IL304242A (da) |
| WO (1) | WO2022148974A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| EP4731638A1 (en) * | 2023-06-23 | 2026-04-29 | BicycleTx Limited | Bicyclic peptide ligands specific for nk cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
| CN115093463A (zh) * | 2014-09-30 | 2022-09-23 | 波利弗尔股份公司 | β-发夹肽模拟物 |
| WO2018222987A1 (en) * | 2017-06-01 | 2018-12-06 | Tarveda Therapeutics, Inc. | Targeted constructs |
| JP7670481B2 (ja) * | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CN111902429A (zh) * | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| CA3099308A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| US12492224B2 (en) * | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
-
2022
- 2022-01-10 DK DK22700425.6T patent/DK4274838T3/da active
- 2022-01-10 AU AU2022206394A patent/AU2022206394A1/en not_active Abandoned
- 2022-01-10 ES ES22700425T patent/ES2992468T3/es active Active
- 2022-01-10 EP EP22700425.6A patent/EP4274838B1/en active Active
- 2022-01-10 US US18/271,353 patent/US20240108738A1/en active Pending
- 2022-01-10 JP JP2023541304A patent/JP2024502351A/ja active Pending
- 2022-01-10 WO PCT/GB2022/050043 patent/WO2022148974A2/en not_active Ceased
- 2022-01-10 CA CA3217018A patent/CA3217018A1/en active Pending
-
2023
- 2023-07-04 IL IL304242A patent/IL304242A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022148974A3 (en) | 2022-12-15 |
| JP2024502351A (ja) | 2024-01-18 |
| ES2992468T3 (es) | 2024-12-12 |
| EP4274838B1 (en) | 2024-09-25 |
| IL304242A (en) | 2023-09-01 |
| WO2022148974A2 (en) | 2022-07-14 |
| CA3217018A1 (en) | 2022-07-14 |
| US20240108738A1 (en) | 2024-04-04 |
| AU2022206394A1 (en) | 2023-08-24 |
| EP4274838A2 (en) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4274838T3 (da) | Bicykliske peptidligander, der er specifikke for NK-celler | |
| DK3810167T3 (da) | Bicykliske peptidligander, der er specifikke for nectin-4 | |
| LT3727461T (lt) | Bicikliniai peptidiniai ligandai, specifiški epha2 | |
| IL283873A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| IL283874A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| IL276803A (en) | Peptide ligands in multimeric cycles | |
| EP3813829A4 (en) | LIGANDS FOR CEREBLON (CRBN) | |
| GB201900526D0 (en) | Bicyclic peptide ligands specific for caix | |
| BR112018068702A2 (pt) | inibidores bicíclicos em ponte de menin-mll e métodos de uso | |
| MX2017012805A (es) | Complejo de unión a antígenos con actividad agonista y métodos de uso. | |
| DK3589655T3 (da) | Tandem diabody til cd16a målrettet nk-celle optagelse | |
| GB201900528D0 (en) | Bicyclic peptide ligands specific for integrin AVB3 | |
| IL285617A (en) | Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers | |
| GB201900527D0 (en) | Bicyclic peptide ligands specific for integrin avb3 | |
| EP3911323A4 (en) | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | |
| DK3778142T3 (da) | Genkonfigurerbare robotceller til fremstillingsformål | |
| IL280375A (en) | Mr1 restricted t cell receptors for cancer immunotherapy | |
| EP3911325A4 (en) | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | |
| GB2585301B8 (en) | Alternate path manifold life extension for extended reach applications | |
| GB202118153D0 (en) | Bicyclic peptide ligands specific for EphA3 | |
| GB201820326D0 (en) | Bicyclic peptide ligands specific for epha3 | |
| GB202020003D0 (en) | Bicyclic peptide ligands specific for EphA3 | |
| GB201918495D0 (en) | Bicyclic peptide ligands specific for il-46 | |
| GB201820323D0 (en) | Bicyclic peptide ligands specific for tnfalpha | |
| GB202020002D0 (en) | Bicyclic peptide ligands specific for TNFalpha |